Contact allergy to topical clobetasol propionate: A therapeutic paradox

Dear Editor,

Topical corticosteroids are widely prescribed for their potent anti-inflammatory properties. However, a paradoxical reaction may occur when the steroid itself triggers allergic contact dermatitis (ACD).^[1] This manifests as persistent itching or worsening of the dermatitis and poor therapeutic response, which may be mistaken for a flare of the primary disease. Recognizing this possibility requires clinical suspicion when lesions do not improve or worsen at the sites of steroid application. We report a patient with dermatitis who developed ACD after application of a steroid, which was confirmed by patch testing.

A middle-aged male presented with reddish lesions with occasional oozing over both lower limbs for 1 month, with a history of similar episodes in the past. Cutaneous examination revealed ill-defined erythematous and edematous plaques with fissuring and crusting over the legs [Figure 1], along with hyperpigmented plaques over the dorsum of the hands [Figure 1a]. There was no history of similar lesions in the family members. The diagnosis was made clinically based on the morphology. He was treated with antihistamines, liquid paraffin, and a topical combination of Tenovate (clobetasol propionate 0.05%) ointment mixed with petrolatum in a 1:2 ratio. Following the application, there was worsening of erythema and pruritus within a day [Figure 1b and c], raising suspicion of a paradoxical reaction to the topical steroid.

Close

Figure 1: (a) Dermatitic lesions over the legs. (b and c) Exacerbation of lesions following application of the clobetasol–petrolatum combination.

Export to PPT

Patch testing was performed using the Indian standard series (ISS) along with clobetasol propionate mixed in petrolatum (as is). On day 2 (D2), all allergens in the ISS were negative, while the clobetasol–petrolatum combination elicited a positive reaction (+) [Figure 2a]. On D4, the reaction to clobetasol intensified to ++ [Figure 2b]. Petrolatum in the ISS showed no reaction on both D2 and D4. This pattern confirmed sensitization specifically to clobetasol propionate rather than to the vehicle.A diagnosis of steroid-induced ACD was made; the topical steroid was withdrawn, and treatment with antihistamines led to resolution of the dermatitis within 3 weeks.

Close

Figure 2: Patch test reaction to clobetasol propionate in petrolatum. (a) Positive reaction (+) on day 2 (D2). (b) Intensification of the reaction to ++ on day 4 (D4).

Export to PPT

Topical corticosteroids are the most frequently prescribed agents in dermatology because of their potent anti-inflammatory, immunosuppressive, and antiproliferative effects. Despite their therapeutic benefits, they can paradoxically cause ACD, an adverse effect that often mimics treatment failure or disease exacerbation. Steroid-induced ACD is an underrecognized adverse effect, as its clinical presentation closely resembles worsening of the primary dermatosis, often leading to inappropriate escalation of steroid potency and chronicity of lesions.

Differential diagnoses in such cases include autosensitization (id reaction) in long-standing eczema and ACD to components of topical formulations such as vehicles and preservatives (e.g., propylene glycol, lanolin, and parabens). Autosensitization typically presents with symmetrical, widespread eczematous eruptions at sites distant from the primary lesion, whereas in our patient, the exacerbation was localized to the site of steroid application with a clear temporal relationship. Patch testing further excluded allergy to excipients, as petrolatum and other allergens in the ISS were negative.

Large dataset evidence shows that true corticosteroid allergy is uncommon, and clobetasol allergy is particularly rare. In a retrospective analysis of 17,978 patients patch tested by the North American Contact Dermatitis Group,^[2] only 0.32% reacted to clobetasol-17-propionate, confirming its low sensitizing potential.

Sensitization to topical corticosteroids is believed to occur not to the parent molecule but to its degradation products formed within the skin. Epidermal esterases cleave the corticosteroid molecule, particularly at the C21 position, resulting in the formation of reactive intermediates known as corticosteroid glyoxal. These act as haptens by binding to proteins, especially arginine residues, that trigger a type IV delayed hypersensitivity reaction. Structural variations influence allergenicity; halogenation at C6 and C9 stabilizes the molecule and reduces sensitization potential, whereas substitutions at positions such as C11 and methylation at C16 may increase allergenic potential.^[3]

Clinically, primary dermatitis typically responds to topical corticosteroids and emollients, whereas steroid-induced ACD presents with worsening erythema, persistent pruritus, and a paradoxical lack of response or deterioration with continued steroid use. Steroid-induced ACD is usually localized to the site of application, while primary dermatitis may be more widespread. On investigating, patch testing is negative in primary dermatitis (unless another allergen is present) but positive to the offending corticosteroid in steroid-induced ACD. Management differs significantly, as primary dermatitis improves with corticosteroids, whereas steroid-induced ACD requires prompt withdrawal of the offending agent and use of a steroid from a non-cross-reacting group or other immunosuppressants, along with symptomatic treatment.

Cross-reactivity among corticosteroids is well explained by their chemical structure-based classification, first described by Coopman et al.^[4] Steroids are divided into Group A (hydrocortisone type), Group B (triamcinolone acetonide type), Group C (betamethasone type), and Group D, which are further subdivided into D1 and D2. Group D1 includes halogenated, stable esters such as clobetasol propionate and betamethasone dipropionate, whereas Group D2 contains labile esters such as hydrocortisone butyrate. Significant cross-reactivity has been demonstrated, particularly between Group A and B and Group D2, due to metabolic conversion of D2 steroids into group A, like structures within the skin. Early recognition of steroid-induced ACD and identification of the specific chemical group are essential to avoid therapeutic failure and to safely select a non-cross-reactive corticosteroid, ensuring effective disease control without recurrence.